The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
Publication/Presentation Date
5-1-2015
Abstract
OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.
RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.
RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values7.00 (P < 0.001 for all).
CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
Volume
38
Issue
5
First Page
940
Last Page
942
ISSN
1935-5548
Published In/Presented At
Sosenko, J. M., Skyler, J. S., Beam, C. A., Boulware, D., Mahon, J. L., Krischer, J. P., Greenbaum, C. J., Rafkin, L. E., Matheson, D., Herold, K. C., Palmer, J. P., & Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups (2015). The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. Diabetes care, 38(5), 940–942. https://doi.org/10.2337/dc14-2787
Disciplines
Medicine and Health Sciences
PubMedID
25758770
Department(s)
Department of Medicine
Document Type
Article